Combining POLE mutational analysis with immunohistochemical analysis of p53 and mismatch repair markers (PMS-2 and MSH-6) have been proposed to classify the tumors in the four TCGA groups, particularly for high-grade EEC and SC, as a surrogate approach to apply TCGA to clinical practice. This evidence concerns the gene TP53 and exstrophy-epispadias complex.